Sanara MedTech Inc (SMTI) Quote

Anyone following this company? Seems like they are going in the right direction on all fronts. It will be nice to see how the salesforce is doing with sales.

SMTI moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Well that was a fun ride to 20. Just like I predicted, due to the buyback. Now it will be interesting to see how high it rises naturally. The ask after hours is over 36 so evidently someone thinks this will rise with time.

Some individual or entity just put $ 45,000.00 into stock this AM. Seems like a vote of confidence to me.

I would agree.....A company cannot grow without investment..." money begats money, and it's offspring begats more" Growth is essential.

Significantly upped net loss, however they invested heavily in sales. So I see them back on the path to profitability within 3 to 4 quarters. I love how the directors purchased 10m worth of stock in order to fund growth, without nasty dilution. They honestly believe in the potential and put their own large sum of money out there. This will be staying in my Roth until they are bought out in a few years for North of 100 /share.

What are your thoughts?

Any opinions on the 10 Q?

Considering where this stock has come from in the past 12 months....there should be no concern of tax loss selling.

Looking good going forward here with that $ imo...GL

Market Beat Insider Trades, Tuesday Oct 22, 2019

S Oden Howell Jr

BUY....60241 shares @ $ 11.00 for a total of $ 662,600

Transaction Date: Oct 15, 2019

A chunk of change to invest, at least by my standards.

News - Sanara MedTech Inc. Announces Closing of $10,000,000 Private Placement of Common Stock
Wednesday, October 16, 2019 9:00 AM
FORT WORTH, TX / ACCESSWIRE / October 16, 2019 / Sanara MedTech Inc. (OTCQB:SMTI). Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara"), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today that it has closed a private placement offering of 1,204,820 shares of its common stock at a price of $8.30 per share. All shares are being sold by Sanara as newly issued shares. The purchasers in the offering consist of related party entities to three members of Sanara's Board of Directors. The transaction was approved by all of the disinterested Directors of Sanara. The price per share was determined by a special committee of the Board comprised of disinterested Directors who considered an independent third-party valuation of the offering price and other relevant information.

The $10 million of cash proceeds of the offering are expected to be used to fund milestone payments under current and future product license agreements, repayment of indebtedness under Sanara's bank line of credit, and operating expenditures, including clinical studies and continued expansion of Sanara's sales force.

The shares of common stock sold in the transaction have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Sanara MedTech Inc. markets and distributes wound and skincare products to physicians, hospitals, clinics, and all post-acute care settings. Its products are primarily sold in the North American advanced wound care and surgical tissue repair markets.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contact:

Callon Nichols, Director of Investor Relations
713-826-0524
CNichols@sanaramedtech.com

SOURCE: Sanara MedTech Inc.

I know growth is expensive, and sales are strong but I’m looking forward to a stronger P&L from SMTI in 2020!

SMTI- BULLISH BUT WAIT FOR $10 TO GO LONG

The chart of SMTI is bullish and has built a lovely base, $10 looks like a area of strong resistance, so rather than jumping in now maybe a break above that level would provide a better entry point.
Indicators need to correct and reset for a sustained rally.

Today also.....the trend is our friend.

Nice little bump today!

BEWARE....the devil is on the bid at $ 6.66 Must be running out of souls to gather....now expanding his/her operations. Gotta keep that heat on no matter what.

IHub still doesn’t recognize the SMTI symbol so I stopped using the app

What is also wired is E-Trade is showing them as being on NASDAQ but Nasdaq shows them as OTC???

Why does no one here want to actually talk about this company? Are you all day traders?

Thus company is so weird. They increased a credit line, and as far as I know they are still unprofitable. They want to re purchase 5 percent of the outstanding shares. At today's prices that would be over a half million dollars. I feel like that money would go to better use hiring a profits and loss specialist. I feel as though they would need to direct purchase from Mr Nixon, who would be selling at a loss with today's price. I would be very surprised why he would do that. Buying open market would drive the stock price up past $20 a share due to lack of volume. We'll see what happens.

Does anyone have any thoughts about the below?

Approval of Stock Purchase Program

The Company's Board of Directors has authorized the Company to purchase up to 5.0% of the current outstanding shares of the Company's common stock from time to time in the open market or through privately negotiated transactions at prevailing market prices, depending on market conditions. The repurchase program has no time limit and may be discontinued at any time, however the Company will use its best efforts to complete the repurchase program by the end of 2019. All shares repurchased, whether through open market or privately negotiated transactions, will be restored to the status of authorized but unissued stock.

Ron Nixon, Executive Chairman of the Board, stated, "The Board fundamentally believes that the Company's stock is undervalued at current prices and the stock repurchase program provides a meaningful way to deliver value to our shareholders."

Someone did a tidy little trade early last week.....1900 shares bought at $ 3.70 early morning and sold late afternoon for $ 5.00. Talk about being nimble in the market.

Effective June 7,2019 WNDMD will change to SMTI:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Really not too bad of a report. 2.49M in rev and cost of goods .29M. Margin is still looking really good, and they are growing again. They will be profitable in the next quarter or so.

Some good news this AM....three new products in the works.

Thank you!

I messaged Charles Schwab today and they are expecting it to transfer either today or tomorrow.

Can anybody see the new ticker on IHub?

Mine were converted on Friday.

Has anyone had their shares converted yet. I see they are now listed under the new ticker symbol WNDMD.

WNDM: effective May 10,2019 Wound Management Technologies Inc. will change to Sanara MedTech Inc. and a one for 100 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

.01 incoming.

Thank you

1:100 R/S Tomorrow, per FINRA: https://otce.finra.org/otce/dailyList

WNDMD

Name Change: Sanara MedTech Inc.

I would agree. The volume has dropped to almost nothing . I thought the reverse spit was suppose to happen before the end if last month?

I think everyone is waiting for the reverse split to happen.

Does this stock still trade???

Thanks! Hopefully it will stock or better yet go up!

There is your .06! Hope nobody drives it back down!

Thank you to who ever bought 500 shares at .05 hopefully it will hold or even help drive the price up! We should be seeing the reverse split soon!

I would feel better if the price was closer to .06 when the reverse stock swap takes place but not sure we will be there. The volume is almost nonexistent !

Not today! I wonder what the hold up is on the reverse split?

The trading volume has almost stopped! I guess everyone is waiting for the reverse split.

I tried...but somebody keeps driving it back down?!?!

Somebody is trying to help move the price up. 1000 shares at .059

Does any know what the date is for the reverse stock split?

I threw a little more at it at the EOT to get it up to .05 but it didn’t help much! I guess we will see what happens next week!

I guess no one has anything to say until we have the reverse stock split . It seems as if the stock has all but stopped trading.

I would have to agree. It sure seems like the stock is being forced down. I would have thought that it would run up before the reverse split.

After yesterday trading it looks like somebody wants the stock price at .05 at the split?!!!

These guys lost over $500,000 in the last quarter, yet they want to reverse split their shares and "uplist". This is done with far too much haste. They need to figure out how to keep the SGA low, while maintaining margin. I likely will not buy any more until I see a positive trend with net income. All the "sales" people they added do not seem to be adding to the top or the bottom line. Michael Carmena should know better than this.